FDA 483 - Boston Scientific Corporation - March 28, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Boston Scientific Corporation, a combination drug manufacturer in Dorado, PR, received a Form 483 with seven observations. The inspection revealed significant deficiencies in the firm's quality systems, including inadequate stability testing, lack of yield calculations, incomplete batch records, and improper storage of active pharmaceutical ingredients. Additionally, issues were noted with reserve sample examination, facility maintenance, and follow-up on drug complaint investigations.
ID · 3ff5110d-4e21-448a-971a-827202c6ccb6